Literature DB >> 2210690

Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process.

J P Greer1, K E Salhany, J B Cousar, J P Fields, L E King, S E Graber, J M Flexner, R S Stein, R D Collins.   

Abstract

Some patients with cerebriform T-cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transformation at the initial diagnosis while the median time from diagnosis to transformation in the other 13 patients was 16 months (range: 3 months-6 years). Thirteen had transformation extracutaneously: lymph nodes (eight), central nervous system (two), and other extranodal sites (three). T cell markers were identified in all cases; of 15 cases with complete phenotypes, there were eight T-helper, three T-suppressor, and four aberrant T phenotypes. Serology for human T-leukemia virus-I (HTLV-I) was negative in eight patients tested. Median survival from diagnosis was 27 months compared to 53 months in 53 patients without transformation (p = 0.003). Despite combination chemotherapy in 12 patients following transformation, median survival after transformation was 12 months and only 7 months with extracutaneous disease. The likelihood of transformation could not be predicted by the initial histology, immunophenotype, or stage of disease.

Entities:  

Mesh:

Year:  1990        PMID: 2210690     DOI: 10.1002/hon.2900080406

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  7 in total

1.  Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.

Authors:  Melissa Pulitzer; Patricia L Myskowski; Steven M Horwitz; Christiane Querfeld; Brian Connolly; Janet Li; Rajmohan Murali
Journal:  Pathology       Date:  2014-12       Impact factor: 5.306

2.  Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.

Authors:  M H Vermeer; F A Geelen; J A Kummer; C J Meijer; R Willemze
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  CD30 expression and proliferative fraction in nontransformed mycosis fungoides.

Authors:  James T Edinger; Beth Z Clark; Brian E Pucevich; Larisa J Geskin; Steven H Swerdlow
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

Review 4.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

5.  Development of a plaque infiltrated with large CD30+ T cells over a silicone-containing device in a patient with history of Sézary syndrome.

Authors:  Anna K Engberg; Christopher G Bunick; Antonio Subtil; Christine J Ko; Michael Girardi
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

6.  Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.

Authors:  Seçil Vural; Bengü Nisa Akay; Ayşenur Botsalı; Erden Atilla; Nehir Parlak; Aylin Okçu Heper; Hatice Şanlı
Journal:  Turk J Haematol       Date:  2017-05-23       Impact factor: 1.831

7.  Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.

Authors:  Alexandra C Hristov; Trilokraj Tejasvi; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2021-08-02       Impact factor: 13.265

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.